Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy

Katya C Corado
Margaret R Caplan
Eric S Daar

Department of Medicine, Division of HIV Medicine, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center, Torrance, CA, USA

Abstract: As people live longer with HIV infection, there has been a resurgence of interest in challenging the use of three-drug therapy, including two nucleoside reverse transcriptase inhibitors plus a third drug, as initial treatment of HIV infection or for maintenance therapy in virologically suppressed individuals. Although initial studies showed poor efficacy and/or substantial toxicity, more recent regimens have held greater promise. The SWORD-1 and -2 studies were pivotal trials of dolutegravir plus rilpivirine as maintenance therapy in virologically suppressed patients with no history of drug resistance, leading to the US Food and Drug Administration’s approval of the regimen as a small, single tablet. More recently, the GEMINI-1 and -2 studies demonstrated that dolutegravir plus lamivudine is as safe and effective as the same regimen when combined with tenofovir disoproxil fumarate in treatment-naïve individuals. Together, these and other studies of novel two-drug regimens offer the potential for improved tolerability and simplicity, as well as a reduction in cost. We will review historical and recent trials of two-drug therapy for the treatment of HIV-1 infection.

Keywords: two-drug therapy, HIV-1 infection, treatment strategies, initial therapy, maintenance therapy

Introduction

Antiretroviral therapy (ART) for the treatment of HIV-1 infection has evolved significantly since the beginning of the epidemic. In the USA, the Food and Drug Administration (FDA) first approved zidovudine (ZDV), a nucleoside reverse transcriptase inhibitor (NRTI), in 1987 for the treatment of HIV-1-infected individuals.1 Although NRTIs have remained the mainstay of ART for the past 30 years, many lessons were learned from the initial use of ZDV as monotherapy. These lessons included the fact that the high level of viral replication and error-prone reverse transcriptase enzyme results in the rapid development of drug-resistant virus.2,3 In addition, ZDV and other early NRTIs induced mitochondrial dysfunction, which led to observed toxicities, such as hematological derangements, liver injury, lactic acidosis, myopathy, and lipodystrophy.4-6

In the decade that followed the FDA approval of ZDV, other NRTIs became available and were utilized either as monotherapy or in combination with each other.7 Unfortunately, didanosine (1991), zalcitabine (1992), and stavudine (1994), either alone or in combination, were associated with substantial toxicity or did not lead to complete viral suppression, consistently allowing for the emergence of broad NRTI resistance. In 1996, presentations at the 11th International AIDS Conference highlighted the effectiveness of combination ART, with triple-drug therapy. These data supported the recommendation of using two NRTIs, forming the “NRTI backbone,”
along with a third agent, such as a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI), as preferred first-line treatment options. Since that time, new ARV classes, such as integrase strand transfer inhibitors (INSTIs), have been developed and approved as components of first-line therapy. These include raltegravir (RAL) approved in 2007, elvitegravir (EVG) as part of a fixed dose combination in 2012, dolutegravir (DTG) in 2013, and bictegravir (BIC) in 2018, all of which are recommended for first-line therapy along with two NRTIs.

Although newer NRTIs, such as abacavir (ABC), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), are better tolerated than earlier generations, they continue to have tolerability and toxicity issues, such as hypersensitivity reactions, renal and bone impairment, and possible association with cardiovascular events.

In order to further minimize toxicity and simplify regimens, several studies have attempted to deviate from the use of the two-NRTI backbone plus a third drug for initial and maintenance therapy. This review will focus on two-drug therapy for HIV-1-infected people. Key trials from each of the following sections, ie, large, randomized, or pivotal proof-of-concept trials, are highlighted in Tables 1–4.

### Treatment-naïve two-drug regimens

While the use of an NRTI backbone currently remains part of all recommended first-line regimens, an NRTI-sparing regimen or a regimen that does not include two NRTIs may be preferred in select cases. Before considering studies that deviate from the two-NRTI plus a third drug paradigm, it is important to review lessons learned from early studies attempting induction with standard ART and then switching to a fewer than three-drug regimen. The Trilège study enrolled 378 participants who were ART naïve and given 3 months of ZDV, lamivudine (3TC), and indinavir (IDV). Participants who attained a viral load of less than 500 copies/mL were then randomized into one of three maintenance groups consisting of either continued ZDV,

### Table 1 Two-drug regimens for treatment-naïve individuals: key NRTI-sparing trials

<table>
<thead>
<tr>
<th>Trial (reference)</th>
<th>N</th>
<th>Regimens compared</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTG 5142</td>
<td>757</td>
<td>EFV + 2 NRTIs</td>
<td>Similar virologic efficacy in EFV + 2 NRTIs and LPV/r + EFV, but more cases of resistance in NRTI-sparing regimen</td>
</tr>
<tr>
<td>PROGRESS</td>
<td>206</td>
<td>LPV/r + 2 NRTIs</td>
<td>Similar virologic efficacy; less reduction in GFR and BMD in the NRTI-sparing group</td>
</tr>
<tr>
<td>NEAT</td>
<td>805</td>
<td>DRV/r + 2 NRTIs</td>
<td>Two-drug regimen non-inferior, except in cases of CD4 count &lt;200 cells/mm³. When HIV-1 RNA ≥100,000 copies/mL, more INSTI resistance observed with virologic failure</td>
</tr>
<tr>
<td>MODERN</td>
<td>797</td>
<td>DRV/r + 2 NRTIs</td>
<td>Study closed early on basis of virologic inferiority of the MVC arm</td>
</tr>
</tbody>
</table>

**Abbreviations:** BMD, bone mineral density; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; GFR, glomerular filtration rate; INSTI, integrase strand transfer inhibitor; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; NRTI, nucleotide/side reverse transcriptase inhibitor; RAL, raltegravir.

### Table 2 Two-drug regimens for treatment-naïve individuals: key single-NRTI trials

<table>
<thead>
<tr>
<th>Trial (reference)</th>
<th>N</th>
<th>Regimens compared</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>KALEAD</td>
<td>152</td>
<td>LPV/r + 2 NRTIs</td>
<td>Underpowered study with high discontinuation rates in both groups, &gt;40%, and viral load suppression just above 50% in both groups</td>
</tr>
<tr>
<td>GARDEL</td>
<td>426</td>
<td>LPV/r + 2 NRTIs</td>
<td>Viral suppression similar in both arms; less toxicity and improved tolerability in the 3TC-only arm</td>
</tr>
<tr>
<td>ANDES</td>
<td>145</td>
<td>DRV/r + TDF/FTC</td>
<td>Similar virologic efficacy and tolerability</td>
</tr>
<tr>
<td>PADDLE</td>
<td>20</td>
<td>DTG + 3TC</td>
<td>Proof-of-concept study; 90% viral suppression at week 48; no resistance</td>
</tr>
<tr>
<td>ACTG 5353</td>
<td>120</td>
<td>DTG + 3TC</td>
<td>Week 24 viral suppression was 90%. Enrolled participants with HIV-1 RNA up to 500,000 copies/mL. One participant developed integrase and NRTI resistance</td>
</tr>
<tr>
<td>GEMINI-1 and -2</td>
<td>1,433</td>
<td>DTG + TDF/FTC</td>
<td>Week 48 data show non-inferiority, including those with HIV-1 RNA &gt;100,000 copies/mL. No resistance</td>
</tr>
</tbody>
</table>

**Abbreviations:** 3TC, lamivudine; DRV/r, ritonavir-boosted darunavir; FTC, emtricitabine; DTG, dolutegravir; LPV/r, ritonavir-boosted lopinavir; NRTI, nucleotide/side reverse transcriptase inhibitor; TDF, tenofovir disoproxil fumarate.
3TC + IDV, or ZDV + 3TC, or ZDV + IDV. Median duration of follow-up was 6 months owing to premature termination of the study by the safety monitoring board when it became clear that relapse rates where significantly higher in both two-drug therapy groups. Similar findings were seen in the ACTG 343,42 where, after a 3-month induction with ZDV, 3TC + IDV, 316 participants were randomized to either continue triple therapy, or IDV alone, or ZDV + 3TC, with greater rates of viral rebound in participants not receiving three drugs. From these studies, we learned that regimens with two NRTIs alone or those with one NRTI plus a non-pharmacologically boosted PI, such as IDV, would not be sufficient to consistently maintain viral suppression.

### NRTI-sparing two-drug regimens

Renewed interest in two-drug regimens occurred with the realization that pharmacologically boosted PIs had much higher barriers to resistance than other agents. The desire to pursue two-drug regimens was further fueled by increasing recognition of the long-term adverse events associated with select NRTIs. As a result, most subsequent studies of two-drug therapy focused on NRTI-sparing options. Key studies in this group are summarized in Table 1. ACTG 5142 compared three regimens for initial therapy in 757 treatment-naïve participants with HIV-1 infection; efavirenz (EFV) + two NRTIs, ritonavir-boosted lopinavir (LPV/r) + two NRTIs, or LPV/r + EFV.13 At week 96, virologic efficacy

### Table 3 Two-drug regimens for maintenance: key NRTI-sparing trials

<table>
<thead>
<tr>
<th>Trial (reference)</th>
<th>N</th>
<th>Regimens compared</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>KITE11</td>
<td>60</td>
<td>Current three-drug regimen LPV/r + RAL</td>
<td>Maintenance of viral load suppression of 92% at week 48 in NRTI-sparing arm</td>
</tr>
<tr>
<td>HARNESS34</td>
<td>109</td>
<td>ATV/r + TDF/FTC, ATV/r + RAL</td>
<td>Lower virologic suppression in NRTI-sparing arm</td>
</tr>
<tr>
<td>MARCH41</td>
<td>395</td>
<td>Current three-drug regimen MVC + 2 NRTIs MVC + PI/r</td>
<td>NRTI-sparing arm was inferior</td>
</tr>
<tr>
<td>PROBE42</td>
<td>60</td>
<td>PI/r + 2 NRTIs, DRV/r + RPV</td>
<td>Proof-of-concept study. At week 48, 96.7% in RPV arm still suppressed</td>
</tr>
<tr>
<td>LATTE43</td>
<td>243</td>
<td>CAB 10 mg + RPV, CAB 30 mg + RPV, CAB 60 mg + RPV, EFV + 2 NRTIs</td>
<td>Week 48 data showed 82% suppression in CAB group and 71% in EFV group. CAB 30 mg was shown to be optimal</td>
</tr>
<tr>
<td>LATTE-244</td>
<td>286</td>
<td>CAB 30 mg + 2 NRTIs, LA CAB + LA RPV every 4 weeks, LA CAB + LA RPV every 8 weeks</td>
<td>Similar continued virologic suppression at week 32 and week 96. Injectable found to be well tolerated</td>
</tr>
<tr>
<td>SWORD-1 and -249</td>
<td>1,024</td>
<td>Current three-drug regimen DTG + RPV</td>
<td>In pooled analysis, 95% DTG + RPV maintained viral suppression. Met non-inferiority</td>
</tr>
</tbody>
</table>

**Abbreviations:** ATV/r, ritonavir-boosted atazanavir; CAB, cabotegravir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; LA, long-acting; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; NRTI, nucleotide/side reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; RAL, raltegravir; RPV, rilpivirine; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine; DTG, dolutegravin.

### Table 4 Two-drug regimens for maintenance: key single-NRTI trials

<table>
<thead>
<tr>
<th>Trial (reference)</th>
<th>N</th>
<th>Regimens compared</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>OLE11</td>
<td>250</td>
<td>LPV/r + 2 NRTIs, LPV/r + 3TC</td>
<td>Virologic suppression &gt;86% in both arms, meeting non-inferiority</td>
</tr>
<tr>
<td>ATLAS-M15</td>
<td>266</td>
<td>ATV/r + 2 NRTIs, ATV/r + 3TC</td>
<td>Non-inferiority met; no resistance seen</td>
</tr>
<tr>
<td>SALT33,54</td>
<td>286</td>
<td>ATV/r + 2 NRTIs, ATV/r + 3TC</td>
<td>Non-inferiority met; no resistance seen</td>
</tr>
<tr>
<td>DUAL GESIDA15</td>
<td>249</td>
<td>DRV/r + 2 NRTIs, DRV/r + 3TC</td>
<td>Non-inferiority met; no resistance seen</td>
</tr>
<tr>
<td>ASPIRE34</td>
<td>90</td>
<td>Current three-drug regimen DTG + 3TC</td>
<td>Virologic suppression of 91% in the two-drug arm at week 48</td>
</tr>
</tbody>
</table>

**Abbreviations:** JTC, lamivudine; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravin; LPV/r, ritonavir-boosted lopinavir; NRTI, nucleotide/side reverse transcriptase inhibitor.
was similar in the EFV + two NRTIs and LPV/r + EFV arms (89% vs 83%). However, in cases of virologic failure, resistance occurred more frequently and there was increased toxicity in those using the NRTI-sparing regimen.

LPV/r was further studied in combination with RAL in two studies. The PROGRESS study compared this regimen to LPV/r + two NRTIs, and CCTG 589 study compared it to EFV + TDF + emtricitabine (FTC). Week 96 data from PROGRESS (n=206) showed similar proportions of responders and reported greater reductions in estimated glomerular filtration rate and bone mineral density in the two-NRTI group. A limitation of this study was that it was relatively small and had few enrolled with high baseline plasma HIV-1 RNA levels. CCTG 589 also reported no difference in viral suppression between the two arms (N=52), although there was significantly faster viral decay during the first 2 weeks in the LPV/r + RAL study group.

RAL was further studied in combination with atazanavir (ATV) as well as with boosted darunavir (DRV/r). Ninety-four participants were randomized 2:1 to receive an experimental dose of ATV, 300 mg twice daily, with RAL compared to ritonavir-boosted ATV (ATV/r) + two NRTIs. While week 24 data showed similar efficacy for viral load suppression in both arms, the study was stopped early owing to high rates of hyperbilirubinemia as well as the development of RAL resistance in the NRTI-sparing regimen. The NEAT study was a fully powered randomized trial which had promising results when comparing DRV/r + RAL to DRV/r + two NRTIs. This large European study randomized 805 participants into the two groups, with week 96 data showing treatment failure of 19% in the RAL vs 15% in the two-NRTI group, meeting criteria for non-inferiority. However, the RAL group was virologically inferior for those with baseline CD4 cell count of less than 200 cells/mm³, and more virologic failures and INSTI resistance were observed in those with baseline plasma HIV-1 RNA levels greater than or equal to 100,000 copies/mL. Inferior efficacy was also observed in participants with lower CD4 cell counts and higher HIV viral loads enrolled in the smaller single-arm ACTG 5262 study, where 112 individuals were given DRV/r + RAL.

The CCR5 antagonist maraviroc (MVC) has also been examined in combination with different boosted PIs. A small study comparing LPV/r + MVC vs LPV/r + two NRTIs enrolled 50 participants; week 48 data showed 100% viral suppression in the MVC and 96% in the two-NRTI arm. Another small study (N=98) compared ATV/r + MVC (n=32) vs two NRTIs + one NNRTI or a PI. Participants in both groups experienced similar percentages of viral load suppression at week 48. However, these results did not hold true in larger studies comparing ATV/r + MVC vs ATV/r + two NRTIs (N=121), where similar viral load suppression was achieved at week 48, except in those with baseline plasma HIV-1 RNA greater than 100,000 copies/mL, where the MVC group was virologically inferior. In the MODERN trial, the largest trial studying a boosted PI combined with MVC, DRV/r + MVC vs DRV/r + two NRTIs, 797 participants were enrolled, and the study was closed early owing to virologic inferiority in the MVC group (viral load suppression of 77.3% for MVC vs 86.8% for the two-NRTI group).

Single-NRTI two-drug regimens

While the studies in the previous subsection focused on NRTI-sparing regimens, two-drug regimens using a single NRTI, such as TDF or 3TC, along with a second drug of a different class have also been studied in treatment-naïve individuals. Key studies in this group are summarized in Table 2. The KALEAD study evaluated TDF + LPV/r, both given once daily. The trial, the largest trial studying a boosted PI combined with MVC, DRV/r + MVC vs DRV/r + two NRTIs, 797 participants were enrolled, and the study was closed early owing to virologic inferiority in the MVC group (viral load suppression of 77.3% for MVC vs 86.8% for the two-NRTI group).

Because 3TC is an NRTI without major side effects, the GARDEL study compared LPV/r (400/100 mg twice daily) + 3TC (150 mg twice daily) to LPV/r (400/100 mg twice daily) + two NRTIs. The study randomized 426 participants, with 48-week data demonstrating viral suppression rates of 88.3% in the 3TC and 83.7% in the two-NRTI arm, including those with baseline plasma HIV-1 RNA greater than or equal to 100,000 copies/mL. It was noted that toxicity- and tolerability-related discontinuations were more common in the two-NRTI group. While this was an encouraging result, pill burden and twice-daily dosing used in this study remained a challenge. In addition, the expected gastrointestinal and metabolic disturbances with LPV/r were problematic. The first Phase of the ANDES study evaluated the better tolerated boosted PI, DRV/r + 3TC (n=75) compared to DRV/r + TDF/FTC (n=70), and demonstrated viral suppression at 48 weeks.
in 93% and 94%, respectively, with similar tolerability. The plan was to assess the results of the first Phase and, if promising, to expand the sample size to generate a fully powered clinical trial of this novel two-drug regimen.

DTG has emerged as an INSTI with a high barrier to resistance, minimal drug–drug interactions, good tolerability, and ease of administration, given once daily with or without food. As noted, all promising two-drug regimens following Trilège and ACTG 343 have included a boosted PI as the sole high-barrier-to-resistance drug. DTG may now offer another high-barrier-to-resistance option. The PADDLE study was a first attempt to assess whether DTG could be used as part of a two-drug regimen. This proof-of-concept study evaluated the efficacy, safety, and tolerability of DTG + 3TC given once daily to 20 treatment-naive individuals with plasma HIV-1 RNA of less than or equal to 100,000 copies/mL and CD4 cell counts greater than 200 cells/mm$^3$. All participants were suppressed by week 8, and week 48 data showed that 90% (18/20) maintained viral suppression. Of the two individuals not suppressed at week 48, one died by suicide, an event not thought to be study-drug related, and the other had low-level viremia that resuppressed without change in therapy. No major tolerability or toxicity issues were observed. This study was followed by ACTG 5353, which enrolled 120 treatment-naive participants with baseline plasma HIV-1 RNA less than 500,000 copies/mL into a single-arm study of DTG + 3TC given once daily. This study demonstrated high levels of virologic suppression, with similar outcomes in those with baseline plasma HIV-1 RNA levels less or equal to and greater than 100,000 copies/mL. However, there was a single individual who selected for integrase resistance and NRTI resistance mutations, which had not previously been seen in any treatment-naive trial of DTG + two NRTIs.

As follow-up to PADDLE and ACTG 5353, two identical Phase III trials, GEMINI-1 and GEMINI-2 (NCT-02831673 and NCT-02831764), are ongoing at the time of writing this review, evaluating DTG + 3TC vs DTG + TDF/FTC for treatment-naive individuals with plasma HIV-1 RNA levels of 1,000–500,000 copies/mL. Week 48 primary outcome data were presented at the 22nd International AIDS Conference: 1,433 participants were randomized 1:1 into the above groups, with approximately 20% having viral loads above 100,000 copies/mL and median CD4 cell counts of approximately 400 cells/mm$^3$. Pooled snapshot outcomes at week 48 showed 91% viral load suppression in the DTG + 3TC and 93% in the DTG + two-NRTI arm, meeting criteria for non-inferiority, with similar results seen in those with baseline plasma HIV-1 RNA levels greater than 100,000 copies/mL. Of the six participants on the two-drug and four on the three-drug regimen who met criteria for protocol-defined virologic failure, none developed INSTI or NRTI resistance mutations. It is important to note that for pooled outcomes at week 48 for the subgroup with baseline CD4 cell counts less than 200 cells/mm$^3$, snapshot analysis showed virologic suppression of 79% in the DTG + 3TC vs 93% in the DTG + two-NRTI group. This difference disappeared in the treatment-related discontinuation = failure analysis. The investigators noted that the difference was not driven by increased rates of virologic failure. In fact, of the 13 participants who were considered snapshot non-response in the DTG + 3TC arm, two resuppressed on the same regimen, two discontinued owing to adverse events (tuberculosis and Chagas disease), two had protocol violations, two were lost to follow-up, one withdrew consent, one withdrew to start hepatitis C therapy, and one changed ART as a result of incarceration. In addition, safety and tolerability profiles were comparable between the two groups.

**Maintenance therapy in virologically suppressed individuals**

Given the disappointing results of earlier induction–maintenance strategies for the treatment of HIV-1-infected people, such as in Trilège and ACTG 343, studies of dual ART strategies were abandoned for nearly a decade. A resurgence of studies assessing the safety and efficacy of two-drug regimens for maintenance therapy in virologically suppressed individuals has occurred to enhance convenience and tolerability, and potentially reduce costs. The following subsections will review studies of NRTI-sparing two-drug regimens (Table 3) and single-NRTI-containing two-drug regimens (Table 4) for maintenance of viral suppression.

**NRTI-sparing two-drug regimens**

Similarly to the interest in using boosted PIs + INSTIs in HIV treatment-naive individuals, several small studies have evaluated this combination as maintenance therapy, as summarized in Table 3. The KITE Study randomized (2:1) 60 individuals without a history of virologic failure and on a stably suppressive regimen for at least 6 months to receive LPV/r + RAL or to continue on their current three-drug regimen. Week 48 data showed maintenance of viral load suppression in 92% of those in the RAL vs 88% in the three-drug study arm.

In contrast, ATV studies did not yield the same results as the LPV/r-based regimens. A retrospective study of the Dat’AIDS cohort followed patients who switched to...
ATV + RAL or ATV/r + RAL between 2008 and 2014 for up to 96 weeks. The cohort (N=283) was not an optimal study population, with 45% having a history of virologic failure, 20% having detectable viral load at the time of starting two-drug therapy, and 47% switching to two-drug therapy owing to ART-related adverse effects. While no difference was found between the boosted and unboosted ATV groups, cumulative percentages of participants remaining free of therapeutic failure at week 48 (65.4%) and week 96 (53.4%) were low. Another retrospective trial with unboosted ATV + RAL showed similarly concerning results (N=102, 18.6% failure at 123 weeks). Both of these trials reported frequent selection for RAL resistance. HARRNESS was a prospective trial comparing ATV/r + RAL vs ATV/r + two NRTIs for maintenance therapy in individuals who did not have a history of virologic failure or exposure to ATV or RAL. Results at 48 weeks supported conclusions of the retrospective trials, with 69.4% in the RAL group maintaining virologic suppression vs 86.5% of those in the two-NRTI group. In a more promising small Japanese study of boosted DRV, 28 stably suppressed individuals without a history of virologic failure switched from LPV/r + two NRTIs to DRV/r + RAL, with 100% maintaining virologic suppression at week 48.

The novel combination of RAL and an NNRTI has been evaluated for maintenance therapy in small studies. RAL + etravirine (ETR) was examined in a small retrospective (N=18), an observational (N=25), and a prospective trial (N=38). These studies showed rates of viral suppression at week 48 to often be higher than 80%; however, they were small and not randomized, and when virologic failure was seen, resistance was often documented to RAL and/or ETR.

As in the ART-naïve trials with dual therapy, MVC did not perform well in two-drug maintenance regimens. The MARCH study took individuals who were virologically suppressed on a boosted PI + two NRTIs and placed them into one of three study arms: continue current therapy, replace the boosted PI with MVC, or replace the two-NRTI with MVC (MVC + boosted PI). Results at 48 weeks showed ongoing virologic suppression of 97.6%, 93.6%, and 84.1%, respectively, demonstrating inferiority of the NRTI-sparing regimen. Similarly, high rates of virologic failure in the MVC + DRV/r arm of the GUSTA trial led to early study termination.

Perhaps the most promising NRTI-sparing maintenance studies utilized rilpivirine (RPV) with a boosted PI or INSTI. In a proof-of-concept study, 60 participants with no previous resistance to study drugs who were stably suppressed on ART were continued on a boosted PI + two NRTIs or switched to DRV/r + RPV. At 48 weeks, 93.4% and 96.7% of participants continued to be virologically suppressed, respectively. In addition, there has been much enthusiasm about the results of newer INSTI medications combined with RPV. Cabotegravir (CAB) is a new INSTI that is a structural analog of DTG, having a half-life of 40 hours with oral dosing and minimal drug interactions. It has been studied in oral form in combination with oral RPV in the LATTE study and in a long-acting (LA) injectable form along with injectable LA RPV in LATTE-2. In LATTE, 243 participants were assigned 1:1:1:1 to receive oral CAB (10 mg, 30 mg, 60 mg) or EFV 600 mg along with two NRTIs for the first 24-week induction period. Those virologically suppressed at week 24 continued to the maintenance Phase (86% CAB group, 74% EFV group), with those on CAB having NRTIs switched to oral RPV 25 mg, with the others remaining on EFV + two NRTIs for 72 weeks. Week 48 data demonstrated that 82% in the CAB group and 71% in the EFV group were virologically suppressed, and at week 96, 76% and 63% had undetectable levels of plasma HIV-1 RNA, respectively. Combined efficacy and safety results showed that a CAB dose of 30 mg was optimal. In LATTE-2, treatment-naïve individuals were given a 20-week induction with oral CAB 30 mg + ABC/3TC, and once virologically suppressed, randomized to intramuscular LA CAB + LA RPV at 4-week (400 and 600 mg, respectively) or 8-week (600 and 800 mg, respectively) intervals, or to continue oral therapy. Of the 286 participants followed during the maintenance period, viral suppression was observed at 32 weeks in 91%, 94%, and 95%, respectively. Week 96 data demonstrated viral suppression of 84%, 87%, and 94%, respectively. Injectable formulations were found to be well accepted and tolerated. Fully powered Phase III registrational maintenance trials are fully enrolled and in follow-up and will compare two NRTIs with INSTI given once daily to dosing every 4 weeks with LA CAB + LA RPV (ATLAS, NCT02951052 and FLAIR, NCT02938520) and dosing every 4 weeks vs every 8 weeks with the LA preparations (ATLAS-2M, NCT03299049). Promising findings were also seen with the use of DTG + RPV as maintenance therapy. An Italian observational cohort study followed 132 patients who were switched by their providers for clinical reasons to DTG + RPV. Forty-three percent had at least one failure with previous ART, 45% had reverse transcriptase mutations, including to RPV, and one had INSTI resistance. Despite this, viral suppression was maintained in 81% at week 24 and in 90.9% at week 48, with similar findings seen at week 96.
are recently published Phase III studies. These identical studies randomized 1,024 individuals, who were on their first or second ART regimen without history of virologic failure, to switch to DTG + RPV or continue their current regimen. At week 52, those who had continued on their current regimen were also switched to DTG + RPV. At the time of enrollment, study subjects had been on a stable regimen for an average of over 4 years, with approximately 70% receiving TDF and FTC as their NRTI backbone. Week 48 data showed that 95% of SWORD-1 and 94% of SWORD-2 participants on DTG + RPV had viral loads less than 50 copies/mL compared to 96% of SWORD-1 and 94% of SWORD-2 subjects who remained on their original ART. In pooled analysis of the intention-to-treat population, 95% maintained viral loads less than 50 copies/mL in both treatment groups, meeting non-inferiority criteria. In 2017, the FDA approved the combination DTG + RPV as a single-pill form.

Single-NRTI two-drug regimens

Several studies have assessed the safety and efficacy of a single NRTI plus a second drug for maintenance of viral suppression. Key studies in this group are summarized in Table 4. The COOL study enrolled 143 participants who were suppressed on EFV, 3TC + TDF for at least 6 months and randomized them to receive EFV + TDF or remain on triple therapy. Viral suppression at 48 weeks was maintained in 81.7% and 97.2%, respectively, with the two-drug regimen not meeting prespecified non-inferiority criteria. In addition, three individuals from the two-drug regimen group developed EFV resistance. Once again, the COOL study appears to confirm that a two-drug regimen needs at least one active agent with a high barrier to resistance.

Several studies evaluated a boosted PI + 3TC for maintenance. In a non-inferiority trial, 250 virologically suppressed individuals on LPV/r + either 3TC or FTC + a second NRTI for at least 6 months and no history of virologic failure were randomized to continue triple therapy or switch to LPV/r + 3TC. At 48 weeks, 86.6% and 87.8% maintained viral suppression, respectively, meeting non-inferiority criteria. One person in the two-drug arm with virologic failure developed 3TC resistance. ATLAS-M and SALT were large non-inferiority trials studying ATV/r + 3TC for maintenance. In ATLAS-M, 266 participants were on ATV/r + two NRTIs with undetectable viral loads and no history of virologic failure and were randomized to either continue their current regimen or switch to ATV/r + 3TC. Non-inferiority was met when 79.7% and 89.5% of participants, respectively, remained virologically suppressed. In fact, the two-drug arm was found to be superior. The SALT trial enrolled 286 individuals with no history of drug resistance or treatment failure and an undetectable viral load for at least 6 months to receive ATV/r + two NRTIs or ATV/r + 3TC. Sixty-five percent of individuals had already been on a PI-based regimen, 33% were on an NNRTI-based regimen, and 82% had experience with TDF. At 48 weeks, virologic suppression was maintained in 78% in the two-NRTI arm and 84% in the 3TC arm, meeting non-inferiority, which was upheld at 96 weeks with virologic suppression in 73.9% and 74.4% of participants, respectively. Of note, neither ATLAS-M nor SALT demonstrated selection of drug resistance in those randomized to the two-drug study arm.

DTV/r has also been studied in combination with 3TC in the DUAL GESIDA, a non-inferiority trial in Spain where 249 participants were on DRV/r + two NRTIs (either TDF/FTC or ABC/3TC) with no history of resistance and an undetectable viral load for at least 6 months. They were randomized to continue the current regimen or switch to DRV/r + 3TC. After 48 weeks of study, the viral load in 92.7% and 88.9% of participants remained undetectable, respectively, meeting non-inferiority, and as in the prior trials, no 3TC resistance was selected for in those experiencing virologic failure.

DTG + 3TC has also been explored for maintenance therapy in several studies. The ASPIRE study randomized in an open-label fashion those virologically suppressed with no history of treatment failure to either continue a standard three-drug regimen (n=45) or to receive DTG + 3TC (n=45). At 48 weeks, virologic suppression was maintained in 91% of those assigned to the two-drug and 89% of those assigned to the three-drug regimen. Two small studies compared remaining on a three-drug regimen to switching to DTG + 3TC or DTG monotherapy, both of which provided promising results from the two-drug regimen but high failure rates in the monotherapy study arms. A fully powered Phase III trial of maintenance therapy with single-tablet DTG/3TC is fully enrolled and in follow-up at the time of writing (TANGO, NCT03446573).

Discussion

This review of two-drug therapies for initial and maintenance treatment of HIV-1-infected people has covered trials from the late 1990s to the present. There are many reasons to study a regimen that contains fewer than three drugs, including the potential for improved tolerability, less toxicity, simpler regimens, and, while not the focus of this review, cost savings, which can be substantial. A major lesson learned from
the earlier trials was that for both initial and maintenance therapy at least one of the components of the two-drug regimen must have a relatively high barrier to resistance. When this was not the case, virologic failure was more common and often associated with the emergence of drug-resistance mutations. While there were mixed results from many studies of two-drug regimens for both initial and maintenance strategies, it was frequently found that the use of MVC was often associated with poor virologic responses, even when used with a boosted PI.

In general, trials of maintenance strategies with two-drug regimens have been more successful than studies initiating treatment-naïve patients on such therapy. The strongest data supporting the use of two-drug regimens for maintenance therapy include a boosted PI + 3TC, the very large SWORD-1 and -2 studies demonstrating high rates of suppression with DTG + RPV, and the very promising early results with LA CAB + LA RPV. Clinicians must remember that most of these studies enrolled stably suppressed subjects without hepatitis B infection since these regimens do not include two active drugs against this virus, and those having no history of treatment failure.

For treatment-naïve patients, the strongest data for two-drug therapy come from the recent results with DTG + 3TC. While longer follow-up for this novel regimen will be important, the data from ACTG 5353, PADDLE, and the GEMINI-I and -2 trials make a strong case for this combination in the setting where resistance data are available, plasma HIV-1 RNA is up to 500,000 copies/mL, and there is no evidence of chronic hepatitis B infection. There are also strong and emerging data on the use of a boosted PI with 3TC, with limited and somewhat weaker data on boosted PIs plus INSTIs.

**Conclusion**

A review of the most significant studies including two-drug regimens for the initial treatment of HIV-1 or to maintain virologic suppression has demonstrated that, after more than two decades of three-drug regimens, a paradigm shift may be on the near horizon. For certain populations where drug toxicity needs to be minimized, where there is intolerance of medications, or if a simpler regimen is desired, using two-drug therapy may be considered a safe and cost-effective alternative.

**Disclosure**

KC Corado has received research support from Gilead Sciences. MR Caplan has received research support from Gilead Sciences, Merck & Co., and Viiv Healthcare. He has also acted as a consultant for Gilead Sciences, Merck & Co., Viiv Healthcare, and Theratechnologies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

**References**


